Poole Jonathan 4
4 · ACADIA PHARMACEUTICALS INC · Filed Mar 20, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) Director Jonathan Poole Receives Award
What Happened
Jonathan Poole, a director of ACADIA Pharmaceuticals (ACAD), received equity awards on March 3, 2026 reported as derivative securities. The filing shows four grants totaling 17,275 underlying shares (7,482 + 3,565 + 4,218 + 2,010). Each grant is reported with an acquisition price of $0.00, indicating these are compensation awards (stock options and/or restricted stock units), not open‑market purchases.
Key Details
- Transaction date: 2026-03-03; reported on Form 4 filed 2026-03-20. Reported acquisition price: $0.00 for each grant (derivative securities).
- Total shares subject to the grants: 17,275 (sum of the four reported awards).
- Shares owned after transaction: Not disclosed in the provided filing.
- Vesting and instrument notes (from the filing footnotes):
- Some awards are stock options that vest in equal annual installments over three years (F1).
- Some options vest quarterly over one year, with final vesting either one year after grant or at the next annual meeting (F2).
- Restricted stock units (RSUs) represent the right to receive one share each (F3) and vest either over three years (F4) or in full on the earlier of one year after grant or the next annual meeting (F5).
- Timeliness: The Form 4 was filed 17 days after the transaction date; Form 4s are normally due within 2 business days, so this filing appears late (no reason for delay is provided).
Context
- These are equity compensation awards (derivative securities). RSUs convert to actual shares only upon vesting; options give the right to acquire shares upon exercise subject to vesting terms. No immediate sale or cashless exercise is reported here.
- Grants to directors are common as part of compensation and do not necessarily indicate a personal market buy/sell decision. The late filing is a compliance note for investors to be aware of.
Insider Transaction Report
Form 4
Poole Jonathan
Director
Transactions
- Award
Director Stock Options (Right to Buy)
[F1]2026-03-03+7,482→ 7,482 totalExercise: $22.50Exp: 2036-03-02→ Common Stock (7,482 underlying) - Award
Director Stock Options (Right to Buy)
[F2]2026-03-03+3,565→ 3,565 totalExercise: $22.50Exp: 2036-03-02→ Common Stock (3,565 underlying) - Award
Restricted Stock Units
[F3][F4]2026-03-03+4,218→ 4,218 total→ Common Stock (4,218 underlying) - Award
Restricted Stock Units
[F3][F5]2026-03-03+2,010→ 2,010 total→ Common Stock (2,010 underlying)
Footnotes (5)
- [F1]The shares subject to the stock option will vest in equal annual installments over three years following the date of grant such that the stock option will be fully vested on the third anniversary of the date of grant.
- [F2]The shares subject to the stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
- [F3]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- [F4]The restricted stock units will vest in equal annual installments over three years following the date of grant such that the restricted stock units will be fully vested on the third anniversary of the date of grant.
- [F5]The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-03-20